Pettee Investors Inc. Sells 4,247 Shares of Becton, Dickinson and Company $BDX

Pettee Investors Inc. reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 69.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,855 shares of the medical instruments supplier’s stock after selling 4,247 shares during the quarter. Pettee Investors Inc.’s holdings in Becton, Dickinson and Company were worth $360,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Activest Wealth Management grew its holdings in shares of Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 97 shares during the last quarter. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $25,000. SOA Wealth Advisors LLC. grew its holdings in shares of Becton, Dickinson and Company by 256.8% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 95 shares during the last quarter. Steph & Co. grew its holdings in shares of Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares during the last quarter. Finally, WPG Advisers LLC grew its holdings in shares of Becton, Dickinson and Company by 64.2% during the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 61 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Trading Up 0.3%

BDX opened at $149.41 on Friday. The firm has a market capitalization of $42.54 billion, a price-to-earnings ratio of 24.37, a PEG ratio of 10.65 and a beta of 0.22. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The company’s 50 day moving average price is $160.69 and its two-hundred day moving average price is $181.96.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The firm had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts predict that Becton, Dickinson and Company will post 12.52 earnings per share for the current year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback program on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.8%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Insider Activity

In other news, Director Bertram L. Scott sold 953 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 1,102 shares of company stock valued at $198,909. 0.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently issued reports on BDX. JPMorgan Chase & Co. decreased their price target on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Barclays initiated coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 target price on the stock. Stifel Nicolaus boosted their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Citigroup reduced their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Finally, Bank of America boosted their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a report on Monday, January 5th. Six equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus price target of $189.08.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.